Literature DB >> 10508207

Apolipoprotein C-III displacement of apolipoprotein E from VLDL: effect of particle size.

E D Breyer1, N A Le, X Li, D Martinson, W V Brown.   

Abstract

ApoC-III and apoE are important determinants of intravascular lipolysis and clearance of triglyceride-rich chylomicrons and VLDL from the blood plasma. Interactions of these two apolipoproteins were studied by adding purified human apoC-III to human plasma at levels observed in hypertriglyceridemic subjects and incubating under specific conditions (2 h, 37 degrees C). As plasma concentrations of apoC-III protein were increased, the contents in both VLDL and HDL were also increased. Addition of apoC-III at concentrations up to four times the intrinsic concentration resulted in the decreasing incremental binding of apoC-III to VLDL while HDL bound increasing amounts without evidence of saturation. No changes were found in lipid content or in particle size of any lipoprotein in these experiments. However, distribution of the intrinsic apoE in different lipoprotein particles changed markedly with displacement of apoE from VLDL to HDL. The fraction of VLDL apoE that was displaced from VLDL to HDL at these high apoC-III concentrations varied among individuals from 20% to 100% its intrinsic level. The proportion of VLDL apoE that was tightly bound (0% to 80%) was found to be reproducible and to correlate with several indices of VLDL particle size. In the group of subjects studied, strongly adherent apoE was essentially absent from VLDL particles having an average content of less than 50,000 molecules of triglyceride. Addition of apoC-III to plasma almost completely displaces apoE from small VLDL particles. Larger VLDL contain tightly bound apoE which are not displaced by increasing concentration of apoC-III.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10508207

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  7 in total

1.  Using primary murine intestinal enteroids to study dietary TAG absorption, lipoprotein synthesis, and the role of apoC-III in the intestine.

Authors:  Javeed Jattan; Cayla Rodia; Diana Li; Adama Diakhate; Hongli Dong; Amy Bataille; Noah F Shroyer; Alison B Kohan
Journal:  J Lipid Res       Date:  2017-02-03       Impact factor: 5.922

2.  Comparison of diets high in monounsaturated versus polyunsaturated fatty acid on postprandial lipoproteins in diabetes.

Authors:  C Madigan; M Ryan; D Owens; P Collins; G H Tomkin
Journal:  Ir J Med Sci       Date:  2005 Jan-Mar       Impact factor: 1.568

3.  Capillary isotachophoresis study of lipoprotein network sensitive to apolipoprotein E phenotype. 1. ApoE distribution between lipoproteins.

Authors:  Alexander D Dergunov; Anne Ponthieux; Maxim V Mel'kin; Daniel Lambert; Sophie Visvikis-Siest; Gerard Siest
Journal:  Mol Cell Biochem       Date:  2009-01-13       Impact factor: 3.396

4.  Tryptophan probes reveal residue-specific phospholipid interactions of apolipoprotein C-III.

Authors:  Candace M Pfefferkorn; Robert L Walker; Yi He; James M Gruschus; Jennifer C Lee
Journal:  Biochim Biophys Acta       Date:  2015-08-22

5.  Associations between apolipoprotein CIII concentrations and microalbuminuria in type 2 diabetes.

Authors:  Zhi-Juan Hu; Lu-Ping Ren; Chao Wang; Bing Liu; Guang-Yao Song
Journal:  Exp Ther Med       Date:  2014-07-07       Impact factor: 2.447

6.  ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance.

Authors:  Bastian Ramms; Sohan Patel; Chelsea Nora; Ariane R Pessentheiner; Max W Chang; Courtney R Green; Gregory J Golden; Patrick Secrest; Ronald M Krauss; Christian M Metallo; Christopher Benner; Veronica J Alexander; Joseph L Witztum; Sotirios Tsimikas; Jeffrey D Esko; Philip L S M Gordts
Journal:  J Lipid Res       Date:  2019-05-14       Impact factor: 5.922

7.  The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma Triglycerides.

Authors:  Hussein N Yassine; Olgica Trenchevska; Ambika Ramrakhiani; Aarushi Parekh; Juraj Koska; Ryan W Walker; Dean Billheimer; Peter D Reaven; Frances T Yen; Randall W Nelson; Michael I Goran; Dobrin Nedelkov
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.